Europe follows FDA to get nod for early stage Alzheimer's therapies

London

EUROPEAN regulators are following in the footsteps of the US Food and Drug Administration (FDA) with plans to help pharmaceutical companies win approval for novel Alzheimer's drugs that treat the earliest stages of the memory-robbing disease.

The European Medicines Agency said on Wednesday that its new guidance would encourage the testing of new medicines even before symptoms appeared, as well as the potential use of biomarkers, such as signs of protein build-up in the brain.